Nath Bio-Genes (India) Ltd

Nath Bio-Genes (India) Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook despite persistent fundamental challenges. The company’s micro-cap status, flat recent financial performance, and subdued institutional interest continue to weigh on sentiment, while modest improvements in technical indicators have prompted a cautious reassessment of its market stance.

Nath Bio-Genes (India) Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 04 March 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 16 March 2026, providing an up-to-date view of the company’s position in the market.

Nath Bio-Genes (India) Ltd touched a fresh 52-week low of Rs.136 on 9 Mar 2026, marking a significant decline amid ongoing challenges reflected in its financial performance and market positioning. The stock’s fall comes despite a brief two-day rally, underscoring persistent pressures within the Other Agricultural Products sector.

Nath Bio-Genes (India) Ltd has been downgraded from a Sell to a Strong Sell rating as of 4 March 2026, reflecting deteriorating technical indicators, flat financial performance, and waning investor confidence. The company’s Mojo Score has dropped to 26.0, signalling significant caution for investors amid persistent underperformance relative to benchmarks and peers.

Nath Bio-Genes (India) Ltd, a player in the Other Agricultural Products sector, has touched a new 52-week low of Rs.137.95, marking a significant decline in its stock price amid broader market fluctuations and sectoral pressures.

Nath Bio-Genes (India) Ltd, a player in the Other Agricultural Products sector, has seen its investment rating upgraded from Strong Sell to Sell as of 25 February 2026. This change reflects a nuanced shift in the company’s technical outlook despite persistent fundamental challenges, signalling a cautious but slightly more optimistic stance among analysts.

Nath Bio-Genes (India) Ltd has been downgraded from a Sell to a Strong Sell rating as of 20 Feb 2026, reflecting deteriorating technical indicators, flat financial performance, and weakening investor confidence. The company’s Mojo Score has fallen to 26.0, signalling significant caution for investors amid a challenging market environment and underwhelming returns compared to benchmarks.

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 February 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Nath Bio-Genes (India) Ltd, a player in the Other Agricultural Products sector, has seen its investment rating downgraded from Strong Sell to Sell as of 4 February 2026. This adjustment reflects a nuanced shift in the company’s technical outlook, valuation, financial trends, and overall quality metrics, signalling caution for investors despite some pockets of valuation attractiveness.

Nath Bio-Genes (India) Ltd., a micro-cap agricultural products company with a market capitalisation of ₹271.00 crores, reported a consolidated net profit of ₹1.60 crores for Q3 FY26 (October-December 2025), representing a sharp 66.80% decline quarter-on-quarter and a 39.62% fall year-on-year. Despite a robust 78.90% YoY revenue increase to ₹65.96 crores driven by seasonal demand, the company's profitability deteriorated significantly as operating margins compressed and interest costs surged to their highest quarterly levels.

Nath Bio-Genes (India) Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 07 Jan 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 27 January 2026, providing investors with the latest perspective on the company’s performance and prospects.

Nath Bio-Genes (India) Ltd’s shares declined sharply to a new 52-week low of Rs.139.8 on 20 Jan 2026, marking a significant downturn amid broader market weakness and sectoral pressures. The stock underperformed its sector and key market indices, reflecting ongoing concerns about the company’s financial performance and investor sentiment.

Nath Bio-Genes (India) Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 2 January 2026, driven primarily by a shift in technical indicators despite ongoing fundamental challenges. The company’s Mojo Score now stands at 31.0, reflecting a cautious but improved outlook amid mixed financial and market signals.

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 03 January 2026, providing investors with the most recent and relevant data to assess the company's outlook.

Nath Bio-Genes (India), a player in the Other Agricultural Products sector, has experienced a shift in market evaluation driven by a combination of technical indicators, valuation metrics, financial trends, and broader market participation. This article analyses the factors influencing the recent revision in the company’s assessment, highlighting key data points and contextualising its performance against sector and market benchmarks.